Time for TED thread on MAM.
I hold so this is probably a blatant ramp, but take a look.
The share is now off its low of 11.5p.
Although many got burnt in thr over hype a few years ago, I think the company
Is now well positioned for advancement.
Management have said that more Nucleopure machine sales are in the pipeline.

Have a listen to TEDs CE here, http://www.wallstreetreporter.com/profiles/TepnelLifeSciences.html

Guardian
Finally, it's worth keeping an eye on Tepnel Life Sciences. Market professionals reckon the AIM-listed DNA technology group has been overlooked in the past month and could now enjoy a good run. They note directors recently bought stock and point out that Tepnel's acquisition of Orchid Diagnostics should significantly boost the company's revenue stream and help it reach a much broader customer base. Tepnel closed 0.5p higher at 13p last night.

Sunday Telegraph
Tepnel is close to completing a second acquisition, having just bought the DNA-testing division of Orchid BioSciences, which allows it to enter the US market and increase the customer base for its DNA technology. Buy at 14.25p, the paper says.
regards
dave

forgot to post the figures!!

++++++++++++++++++++++++
Consolidated Profit & Loss Account for the 6 months ended 30 June 2005

6 months ended 30 Audited 6 months
June 2005(1) Year ended 31 ended 30 June 2004(1)
December 2004
'000 '000 '000
Turnover 6,893 10,193 5,068
Cost of sales (2,804) (5,467) (2,974)
Gross profit 4,089 4,726 2,094

Research and development (953) (1,553) (636)
Sales and marketing (1,421) (2,185) (994)
Administrative expenses (2,106) (2,722) (1,395)
Administrative expenses - - (547) -
exceptional(2)
Total administrative expenses (2,106) (3,269) (1,395)
Total expenses (4,480) (7,007) (3,025)
Operating loss (391) (2,281) (931)
Interest receivable 35 43 26
Interest payable (5) (23) (17)
Loss on ordinary activities before (361) (2,261) (922)
taxation
Taxation 69 19 60
Loss on ordinary activities after (292) (2,242) (862)
taxation
Basic and diluted loss per share 0.1p 1.5p 0.6p



Statement of Total Recognised Gains and Losses for the 6 months ended 30 June
2005


6 months Audited 6 months ended 30
ended 30 June Year ended 31 December June 2004(1)
2005(3) 2004
'000 '000 '000
Loss for the period (292) (2,242) (862)
Currency translation differences on (21) (36) 13
foreign currency net investments
Total gains and losses recognised (313) (2,278) (849)



Consolidated Balance Sheet as at 30 June 2005

30 June 2005(4) Audited 30 June 2004(1)
31 December 2004
'000 '000 '000
Fixed assets
Intangible fixed assets 1,762 1,882 502
Tangible fixed assets 1,675 1,851 1,933
3,437 3,733 2,435
Current assets
Stocks 2,412 2,279 2,245
Debtors: due within one year 3,615 2,932 3,357
Cash at bank and in hand 1,807 2,542 1,474
7,834 7,753 7,076
Creditors: amounts falling due (4,025) (3,927) (4,003)
within one year
Net current assets 3,809 3,826 3,073
Total assets less current 7,246 7,559 5,508
liabilities
Creditors: amounts falling due after - - (64)
more than one year
Net assets 7,246 7,559 5,444

Capital and reserves(5)
Called up share capital 2,129 2,129 1,385
Share premium account 33,588 33,588 30,788
Profit and loss account (28,471) (28,158) (26,729)
Equity shareholders' funds 7,246 7,559 5,444



Consolidated Cash Flow Statement for the 6 months ended 30 June 2005


6 months Audited 6 months
ended 30 June 2005 Year ended 31 December ended 30 June 2004(1)
(6) 2004
'000 '000 '000
Consolidated cash flow statement
Net cash outflow from operating (574) (1,057) (1,389)
activities
Returns on investments and 30 20 9
servicing of finance
Acquisitions - (3,838) (1,967)
Corporation tax - 180 (98)
Capital expenditure (125) (317) 342
Net cash outflow before financing (669) (5,012) (3,103)
Financing (66) 3,310 333
Decrease in cash (735) (1,702) (2,770)


Reconciliation of operating loss to net
cash outflow from operating activities:
Operating loss (391) (2,281) (931)
Depreciation 300 596 324
Amortisation 109 56 -
(Increase)/decrease in stocks (133) 572 (1,250)
(Increase)/decrease in debtors (619) 228 (1,876)
Increase/(decrease) in creditors 160 (227) 2,344
Other non-cash movements - (1) -
Net cash outflow from operating
activities (574) (1,057) (1,389)




Reconciliation of net cash flow to
movement in net funds
Decrease in cash (735) (1,702) (2,770)
Cash outflow from decrease in lease 66 132 65
financing
Issued debt - (550) -
Change in net funds resulting from cash (669) (2,120) (2,705)
flows
Conversion of debt to equity - 550 -
Net funds at beginning of period 2,398 3,968 3,968
Net funds at end of period 1,729 2,398 1,263




Notes

1 The Interim Report for the six months ended 30 June 2005 is unaudited and was approved by
the directors. The financial information set out above does not constitute statutory
accounts within the meaning of section 240 of the Companies Act 1985. The information for
the comparative figures has been extracted from the previously published Interim and Annual
Reports. The Annual Report from which the information for the year ended 31 December 2004
has been delivered to the Registrar of Companies and contained an unqualified audit opinion.

2 The directors do not recommend the payment of an interim dividend.

3 The accounting policies used are consistent with those applied in the latest published
consolidated accounts.

4 Segmental analysis
6 months ended 30 June 2005(7)
Turnover by geographical Research Products Molecular Total
destination and Services Diagnostics
'000 '000 '000
UK 1,624 300 1,924
Rest of Europe 1,111 875 1,986
US 72 1,877 1,949
Asia 6 342 348
Rest of World 63 623 686
2,876 4,017 6,893





Audited
Year ended 31 December 2004

Turnover by geographical Research Products Molecular Total
destination and Services Diagnostics
'000 '000 '000
UK 3,251 326 3,577
Rest of Europe 614 1,786 2,400
US 79 3,271 3,350
Asia 10 462 472
Rest of World 114 280 394
4,068 6,125 10,193


6 months ended 30 June 2004(1)
Turnover by geographical Research Products Molecular Total
destination and Services Diagnostics
'000 '000 '000
UK 1,640 310 1,950
Rest of Europe 340 592 932
US 41 1,771 1,812
Asia 4 1 5
Rest of World 61 308 369
2,086 2,982 5,068





5 The basic and diluted loss per share has been calculated on the following basis:
6 months Audited 6 months ended 30
ended 30 June Year ended 31 December June 2004(1)
2005(8) 2004
Loss for the period (292) (2,242) (862)
('000)
Weighted average no. of 212,927,315 148,403,632 134,244,887
shares

In the current period the average number of shares is the same on a diluted basis.

6 Copies of this statement are being sent to all shareholders and will be available to the public at the
Company's Registered office at Heron House, Oaks Business Park, Crewe Road, Wythenshawe, Manchester M23
9HZ.



--------------------------


(1) Neither audited or reviewed.


(2) Exceptional items comprise costs relating to restructuring (506k) and redundancy costs (41).


(3) Neither audited or reviewed.


(4) Neither audited or reviewed.


(5) All items under capital and reserves are equity.


(6) Neither audited or reviewed.


(7) Neither audited or reviewed


(8) Neither audited or reviewed.


This information is provided by RNS
The company news service from the London Stock Exchange

Morning all,
This bit of press came from the Manchester Evening News( local, but still press!).

+++++++++++++++++++++++++++++

Tepnel heading towards profits
Chris Barry
TEPNEL Life Sciences, the biotech firm specialising in molecular diagnosis, heralded an "excellent" first half performance as sales soared 36 per cent and losses fell by 60 per cent.

The Manchester company, which said earlier this month that it had turned down a takeover approach from an un-named suitor, said it was in good shape to move into profitability.

Sales in the six months to June 30 rose 36 per cent from 5.07m to 6.89m. Losses fell 61 per cent from 920,000 to 360,000.




Tepnel's US-based chief executive Ben Matzilevich said he was "pleased and gratified" with the improved performance.

Alec Craig, the Manchester corporate lawyer who chairs Tepnel, described the performance as "an outstanding success", and said he was confident for the future.

He outlined why the bid approach had been shunned: "The board believed the valuations underestimated the present and future value of Tepnel and consequently were not in a position to recommend to shareholders any of the proposals made."

Tepnel's shares were unchanged at 8.25p, valuing the company at 17.5m.

Nice to see this one doing better, still down on what I paid (just) in 04 but got a nice bit in shares mag today.
2517

Small buying by directors yesterday.
2517

Excellent int. results 0.5m profit and with the benefits of the Livingstone facility from this month turnover should increase quite markedly for the full year. The outlook appears to be very positive.
2517

Tepnel Life Sciences Plc (TED-AIM) Heath Care. Pharmaceuticals and biotechnology. S. P. 8.75p Market Cap 23,669m. Trade 39.

Our share club has voted to open up a position with TED on the pretext that the S.P. will do well over the next few months.

TED, the international Molecular Diagnostics and Research Products & Services group, announces that it has granted, in aggregate, 5,800,000 share awards to
certain employees (but not directors) of the Company under the Tepnel Life
Sciences plc 2006 Long Term Incentive Plan ("Long Term Incentive Plan"). The
Long Term Incentive Plan was introduced by Tepnel in August 2006 to align more
closely management incentives with the interests of shareholders by linking the award to growth in the Company's share price over the 3 year vesting period.

The 5,800,000 nil cost options granted will be released based on the growth in
the Company's share price over the period from the date of grant to the third
anniversary of the date of grant in accordance with the following table:

To find out more about TED click onto www.shareclubuk.co.uk or go to http://tepnel.com for more background information.

Turnover should be well ahead of last year if the Livingstone facility is running to form, looking forward to the finals in march, following on from the good interims.
2517

Even dear old TED is on the rise today.
2517

Good results today.
2517

Substantial underlying organic growth leading to the first year of
significant profitability and operating cash inflows
* Revenue increased by 19% to 17.8m (2006: 15.0m) and by 22% on a constant
currency basis
* Operating profit increased to 1.39m (2006: 0.05m)
* Earnings before interest, tax, depreciation and amortization (EBITDA)
increased by 192% to 2.01m (2006: 0.69m)
* First significant operating cash inflow reported at 1.72m (2006: 0.12m)
* Improvement in gross margin to 57% (2006: 54%)
* Increase in earnings per share to 0.59p (2006: 0.06p)
* Strong sales growth in the Molecular Diagnostics division driven by the
LifeMatch range of products
* Major investment in the future of the Research Products and Services
division with the completion of the new pharmaceutical facility in
Livingston, Scotland and newly launched service lines

True information taken from the Preliminary results for the year ended 31 December 2007

Highlights
Substantial underlying organic growth leading to the first year of significant profitability and operating cash inflows
Revenue increased by 19% to 17.8m (2006: 15.0m) and by 22% on a constant currency basis
Operating profit increased to 1.39m (2006: 0.05m)
Earnings before interest, tax, depreciation and amortization (EBITDA) increased by 192% to 2.01m (2006: 0.69m)
First significant operating cash inflow reported at 1.72m (2006: 0.12m)
Improvement in gross margin to 57% (2006: 54%)
Increase in earnings per share to 0.59p (2006: 0.06p)
Strong sales growth in the Molecular Diagnostics division driven by the LifeMatch range of products
Major investment in the future of the Research Products and Services division with the completion of the new pharmaceutical facility in Livingston, Scotland and newly launched service lines

(TED share price is holding it own at this time follow the true facts at www.shareclubuk.co.uk no head in the sand, no make-believe just good old fashion share trading with the company as it stands today. 5.

When I invest in a company for the first time I invest a adequate trading amount then add to the Investment as and when I can see profits coming in for myself, TED share price trades at 8.88p at that price I hold a shed load of shares. To date I have invested two times. 5.

Tepnel Life Sciences is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Our target markets are pharmaceutical, biotechnology, healthcare, hospitals, academic/research institutes, food manufacturers and regulatory authorities. 5.

Welcome to this Tepnel Life Sciences thread, As I am a registered blind person I can only list an update each week on the thread as information comes in direct from the company, my stock broker and others in the market place. I welcome any contribution to the thread for the benefit of all

The news from the market place is that Tepnel Life Sciences share price is trading at a discounted price of 8.50p giving an opportunity to make profits on the back of the share price. Market Cap is 20.43 million.

TED is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Target markets are pharmaceutical, biotechnology, healthcare, hospitals, academic/research institutes, food manufacturers and regulatory authorities.

The most recent news from the company is that AXA S.A. now hold 27,732,428 voting right shares (16.27%.) of the issued shares. // the Major Investment of AXA S.A. gives a strong influence to Buy shares with TED the comfort factor. /

Positive news Tepnel preferred supplier agreement with AstraZeneca for DNA extraction services is extended. Share price responds by trading up 0.60p to 14p.

myway-------I don't know where you obtained the sp of TED as being 14p, they were as you say up 0.62p on the day, but the sp is 9.62p. I would like to see them @ 14p and maybe we shall see that over the next 12 months or so.
2517

2517GEORGE So sorry I posted the wrong price...
Positive news Tepnel preferred supplier agreement with AstraZeneca for DNA extraction services is extended. The Share price responded by trading up 0.75p to 6.00p since the announcement. Now I understand why AXA S. A , Holds 27,732,428 shares in the company./

myway----you still can't get it right, they have not been as low as 6p for ages.
2517

2517GORGE Today's price 9.755p.

Update I have had a telephone conversation with my contact at Tepnel Life. He informed me that the company was very pleased with business at the present time, TEDs agreement with AstraZenca interacted a major step in the companys marketing, only to be enhanced by the news that TED has signed a two year global distribution agreement with world's largest online supplier of antibodies, Abcam.

At the end of our telephone conversation I felt that the company is now well in line to take on new clients and extra business for their life sciences products. I look forward to the next announcement from the company, I will now increase my stock holdings in the company. /

one you must have